PAH Patient Survey

Real-world patient reported outcomes in patients with pulmonary arterial hypertension (PAH) in Japan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030240326

Enrollment

Registered

2024-09-10

Start date

2026-05-22

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary arterial hypertension PAH

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Participants who are considered as PAH group 1 2.Participants who have both the willingness and ability to provide informed consent in this survey 3.Adult participants who are 18 years old over

Exclusion criteria

Exclusion criteria: 1.Participants who are currently participating in or have previously participated in any Sotatercept clinical trials 2.Participants who are currently participating in PAH or PH related clinical trials 3.Participants who are diagnosed as non-group 1 PH (PH Group 2, 3, and 4) 4.Participants who did not select any listed diagnoses in the screening questionnaires

Design outcomes

Primary

Measure	Time frame
Basic demographic and clinical characteristics of Japanese PAH patients Disease specific QoL of Japanese PAH patients, emPHasis-10	—

Secondary

Measure	Time frame
Health related QoL of PAH patients(EQ-5D-5L) Coefficient of each factor associated with the worse QoL in PAH patients	—

Contacts

Public ContactIchiro Tazaki

MSD K.K.

ichiro.tazaki@msd.com+81-3-6272-1364

Outcome results